Environmental surveillance (ES) for Salmonella Typhi potentially offers a low-cost tool to identify communities with a high burden of typhoid fever. We developed standardized protocols for typhoid ES, including sampling site selection, validation, characterization; grab or trap sample collection, concentration; and quantitative PCR targeting Salmonella genes (ttr, staG, and tviB) and a marker of human fecal contamination (HF183). ES was implemented over 12 months in a historically high typhoid fever incidence setting (Vellore, India) and a lower incidence setting (Blantyre, Malawi) during 2021–2022. S. Typhi prevalence in ES samples was higher in Vellore compared with Blantyre; 39/520 (7.5%; 95% confidence interval [CI], 4.4%–12.4%) vs 11/533 (2.1%; 95% CI, 1.1%–4.0%) in grab and 79/517 (15.3%; 95% CI, 9.8%–23.0%) vs 23/594 (3.9%; 95% CI, 1.9%–7.9%) in trap samples. Detection was clustered by ES site and correlated with site catchment population in Vellore but not Blantyre. Incidence of culture-confirmed typhoid in local hospitals was low during the study and zero some months in Vellore despite S. Typhi detection in ES. ES describes the prevalence and distribution of S. Typhi even in the absence of typhoid cases and could inform vaccine introduction. Expanded implementation and comparison with clinical and serological surveillance will further establish its public health utility.
7 April 2022 in Indian Journal of Medical Microbiology
Salmonella enterica serovar Typhi (S. Typhi) is the causative agent of Typhoid fever. Blood culture is the gold standard for clinical diagnosis, but this is often difficult to employ in resource limited settings. Environmental surveillance of waste-impacted waters is a promising supplement to clinical surveillance, however validating methods is challenging in regions where S. Typhi concentrations are low. To evaluate existing S. Typhi environmental surveillance methods, a novel process control organism (PCO) was created as a biosafe surrogate. Using a previous described qPCR assay, a modified PCR amplicon for the staG gene was cloned into E. coli. We developed a target region that was recognized by the Typhoid primers in addition to a non-coding internal probe sequence. A multiplex qPCR reaction was developed that differentiates between the typhoid and control targets, with no cross-reactivity or inhibition of the two probes. The PCO was shown to mimic S. Typhi in lab-based experiments with concentration methods using primary wastewater: filter cartridge, recirculating Moore swabs, membrane filtration, and differential centrifugation. Across all methods, the PCO seeded at 10 CFU/mL and 100 CFU/mL was detected in 100% of replicates. The PCO is detected at similar quantification cycle (Cq) values across all methods at 10 CFU/mL (Average = 32.4, STDEV = 1.62). The PCO was also seeded into wastewater at collection sites in Vellore (India) and Blantyre (Malawi) where S. Typhi is endemic. All methods tested in both countries were positive for the seeded PCO. The PCO is an effective way to validate performance of environmental surveillance methods targeting S. Typhi in surface water.
23 November 2025 in World Journal of Nuclear Medicine
Protein losing enteropathy (PLE) is usually a diagnosis of exclusion, which requires cumbersome tests to confirm. In the quest for a simpler diagnostic test, we hypothesized that a spot stool sample estimation of α-1 antitrypsin will be sufficient to make a diagnosis of PLE, if we control for serum α-1 antitrypsin concentration and degree of stool dilution. Consecutive patients with a clinical suspicion of PLE and who had been advised a scintigraphy study were recruited after getting informed consent. The study excluded patients less than 1 year of age, pregnant women, and those with a clinical suspicion of chronic pancreatitis. Serum α-1 antitrypsin, spot stool α-1 antitrypsin, and stool elastase was assessed in all the patients. The diagnostic value of the index test was estimated from the patients with positive scintigraphy scan compared with a negative scan, expressed as sensitivity and specificity and the area under the receiver operating characteristic curve (AUROC). A total of 33 patients underwent scintigraphy with a clinical suspicion of PLE. Twenty patients (60%) showed tracer activity in the gut suggestive of PLE. Spot stool α-1 antitrypsin below 0.26 mg/g had a sensitivity of 100% to rule out PLE; however, the specificity was only 46%. Spot stool α-1 antitrypsin/(serum α-1 antitrypsin * elastase) ratio performed similar to spot stool α-1 antitrypsin as a diagnostic test (AUROC: 0.814 [0.61–1.0] vs. 0.796 [0.54–1.0]). Random stool antitrypsin is a sensitive test for diagnosing PLE; however, it lacks specificity. Spot stool α-1 antitrypsin/(serum α-1 antitrypsin * stool elastase) does not provide any additional value in the diagnosis of this syndrome.